Long-term study with @entity12803 ( XXXX ) in the treatment of rheumatoid arthritis.

@entity1 @entity5230 @entity12803 @entity158 @entity490
Thirty @entity1 were allocated in a double-blind study comparing @entity5230 20 mg to @entity12803 20 mg. Both drugs were administered once daily, before breakfast, for a period of 6 months. Clinical evaluations were performed weekly during the first 6 weeks and then monthly. The following parameters were evaluated: Ritchie articular index, @entity158 on movement, @entity158 at rest, grip strength, functional status, and morning stiffness. Laboratory examinations were performed before, on the 42nd day and on the 6th month of therapy. Efficacy was considered favourable in 10 cases treated with @entity12803 and in 12 with @entity5230 and poor in five treated with the former and in three with @entity5230 . Three @entity1 of each group presented side effects of slight intensity. Considering the good results seen in the @entity1 receiving @entity12803 , the treatment was maintained in nine cases for a further period of 6 months. Eleven other @entity1 from the @entity5230 group also received @entity12803 for a further period of 6 months. The efficacy was maintained in all 20 @entity1 . Regarding adverse reactions, one @entity1 complained of @entity490 in the twelfth month of therapy and another @entity1 had a brief episode of meteorism in the ninth month.
